Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial (ZEAL)

De Boer RH, Arrieta O, Yang C-H, Gottfried M, Chan V, Raats J, De Marinis F, Abratt RP, Wolf J, Blackhall FH, Langmuir P, Milenkova T, Read J, Vansteenkiste J

Journal: Journal of Clinical Oncology
Published: March 2011